It is known that centrally injected ghrelin is an anorexigenic peptide in chicken. Its activity is not mediated by NPY/AgRP -producing neurons but through the corticosterone releasing hormone (CRH) -expressing neurons in hypothalamus which activate the hypothalamo-pituitary-adrenal (HPA) axis inducing an increase in plasma corticosterone levels. However, controversial results of peripheral ghrelin effect on appetite have been reported. Thus, the influence of intraperitonealinjected ghrelin on the activity of the HPA axis in Cobb broiler chickens was examined. In addition, the effect of glucocorticoids antagonist (RU486) on the ghrelin activity was also investigated. The intraperitoneal co-injection of CRH-receptor antagonist, astressin, partially attenuated ghrelininduced anorexia and corticosterone release. Co-administration of RU486 significantly enhanced the inhibitory effect of ghrelin on feed intake in 7-day-old broiler chickens. These results indicate that the peripheral ghrelin -induced anorexia is caused by the stimulation of HPA axis in chickens.
INTRODUCTION
The central and peripheral regulatory mechanisms in energy homeostasis, including feed intake and energy expenditure, in avian species have been recently extensively studied (Richards, 2003; Richards and McMurtry, 2010) . Many of neural and endocrine mechanisms identified in mammals as involving in regulation feed intake also have this function in birds. For instance, neuropeptide Y (NPY) and agouti-related protein (AgRP) are mediators of many appetite-stimulatory peptides in central nervous system (CNS) in both groups (Zhou et al., 2005) . However, there are some responses such as ghrelin that are unique to avian.
Ghrelin is an endogenous ligand of the growth hormone secretagagogue receptor (GHS-R) that was first purified from rat stomach and named for its growth hormone (GH) releasing activity (Kojima et al., 1999) . Ghrelin is predominantly produced in the mucosal layer of stomach, although its mRNA has been detected in central nervous system (hypothalamus), pituitary and peripheral (intestine, pancreas, kidney, lung, placenta) tissues as well as in the immune system (Korbonits et al., 2004) . It is known that the principal effects of ghrelin is stimulating GH -release and regulating energy homeostasis . In mammals, ghrelin stimulates feed intake and its orexigenic effect is mediated by NPY/AgRP -neurons projecting from arcuate nucleus (ARC) to paraventricular nucleus (PVN) in the hypothalamus (Wang et al., 2001) .
It was shown that avian ghrelin elevates GH level in dose and time dependent manner (Ahmed and Harvey, 2002; Baudet and Harvey, 2003) . However, the main difference in ghrelin function between birds and mammals relates its role in the regulation of feed intake. There have been reports that centrally injected ghrelin strongly inhibit feed intake in neonatal chicks (Saito et al., 2005; Khan et al., 2006) . Saito et al. (2005) suggested that the inhibitory effect of central ghrelin on feeding is caused by activating the corticotropin releasing hormone (CRH) -producing neurons. Intracerebroventricular (icv) administration of ghrelin stimulated corticosterone release in a dose-and time-dependent manner (Shousha et al., 2005) . Additionally, this effect was completely blocked by CRH receptor antagonist (astressin) injection what suggests that central ghrelin may interact with HPA axis (Saito et al., 2005) . In poultry, the impact of ghrelin administered peripherally produced controversial results from having no effects (Kaiya et al., 2007) to inhibiting (Geelissen et al., 2006) or stimulating (Shousha et al., 2005) feed intake.
Thus, in the present study, it was examined whether exogenously (intraperitoneally; ip) administered ghrelin may induce anorexia by activating the HPA axis.
MATERIAL AND METHODS

Animals
Seven-day-old commercials Cobb broilers (n=222) were purchased from the local hatchery (Brzesko, Poland). They had free access to water and chicken starter diet. Temperature was maintained at 32±2ºC. All experimental procedures followed the guidelines for the care and use of experimental animal at National Institute of Animal Production.
Birds were placed in individual cages 24 h before the experiments. Before each experiment chicken were weighed and distributed into experimental groups so that the average body weight (BW) was as uniform as possible between treatment groups (170.37±13.8 g).
Peptides
Chicken ghrelin was purchased from Phoenix Pharmaceuticals, Inc. (CA, USA and glucocorticoids receptor antagonist (1β-(4-Dimethyl amino) phenyl-17β-hydroxy -17 -(1-propynyl) estra-4,9-dien-3-one; RU 486/Mifepristone) were purchased from Sigma-Aldrich Co (USA). All peptides were dissolved in 0.85% saline containing 0.1% Evans Blue dye (Sigma-Aldrich Co, USA) and injected ip in a volume 20 μl after 3 h of fasting in order to stimulate and synchronize feed intake.
Experimental design
Four experiments were conducted to determine the effect of peripherally injected ghrelin on feed intake by chicken. Except for experiment 1 described below, the remaining experiments involved the measurement of feed intake and/or plasma corticosterone levels. The quantity of feed was determined after 30, 60 and 120 min after the single administration of ghrelin by measuring the disappearance of diet from the pre-weighed feeder with an accuracy of 0.01 g. Plasma corticosterone was determined at 30, 60 and 120 min after ip injection of ghrelin.
In experiment 1, chicken (n=24) were divided into two groups: control fed ad libitum and experimentally fasted for 24 h. During the feed deprivation periods, the chicken had free access to water.
In experiment 2, chicken (n=54) were divided into three groups, and either chicken ghrelin (0.5 or 2 nmol/100 BW) or saline (control) was ip administrated. OCŁOŃ E., PIETRAS M.
Based on the result from experiment 2, the dose of chicken ghrelin 0.5 nmol/100 g BW was used in experiments 3 and 4. In experiment 3, chicken (n=72) were divided into four groups and subjected to the following ip injections: saline (control), chicken ghrelin (0.5 nmol/100 g BW), astressin (6 nmol/chicken) and chicken ghrelin with astressin (0.5 nmol/100g BW and 6 nmol/chicken).
In Experiment 4, chicken (n=72) were divided into four groups: saline (control), chicken ghrelin (0.5 nmol/100 g BW), RU 486 (50 mg/kg BW) and chicken ghrelin with RU 486 (0.5 nmol/100 g BW and 50 mg/kg BW).
At the end of experiments, the chicken were decapitated. Blood samples and tissues (pituitary, proventriculus, adrenal glands) were collected and stored at -80ºC for further RNA isolation and/or ghrelin and corticosterone RIA detection. Tissues were weighed, and homogenized in 50 mM Tris-HCl (pH 7.4). Homogenates were boiled for 20 min to inactivate intrinsic proteases and centrifuged for 30 min at 10,000 g. The supernatants were collected and lyophilized. The appropriate RIA measured total ghrelin after reconstitution in 10 mM phosphate buffer (pH 6.5).
Ghrelin and corticosterone concentrations were measured using a commercial RIA kits (Ghrelin TOTAL Linco, USA and Corticosterone RIA KIT MP Biomedicals, USA) according to the manufacturer's protocol.
RNA extraction and cDNA synthesis
Total RNA was extracted from chicken proventriculus (experiment 1) using the Trizol Reagent (Applied Biosystems, USA) according to the method given by Chomczynski and Sacchi (1987) . Concentration and purity of the RNA samples were determined by UV spectroscopy at 260/280 nm, and integrity was confirmed by electrophoresis through 1% agarose gels stained with ethidium bromide. First strand cDNA was transcribed from 1 μg RNA with MultiScribe Reverse Transcriptase (50 U/μl, Applied Biosystems, USA) using random primers at 25ºC for 10 min followed by 37ºC for 120 min and 85ºC for 5 s (High Capacity cDNA Reverse Trancription Kit, Applied Biosystems, USA). The cDNA was reconstituted in 50 μl of sterilized water and 200 ng of the cDNA solution was used as a template.
Quantitative PCR
Quantitative PCR analysis was performed using the 7500 Real-Time PCR System (Applied Biosystems, USA) with the Universal Master Mix and TaqMan chemistry (Applied Biosystems, USA).
The sequences of ghrl primers and the TaqMan fluorogenic probe are given in Table 1 . The amplicon size was 67 bz. Amplification and detection were carried out in optical-grade 96-well plates with an initial step of 50°C for 2 min, which is the required optimal AmpErase UNG enzyme activity, and then at 95°C for 10 min, to activate the AmpliTaq Gold DNA polymerase and to deactivate the AmpErase UNG enzyme, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Data obtained for ghrelin were compared with data obtained from amplification of reference gene 18sRNA (Applied Biosystems, USA). Data were calculated as 2 -ΔΔCt where ΔC T = C T gene of ghrelin -C T 18sRNA and ΔΔC T is the change between the ΔC T for each sample and the control group. Samples in which no amplified product could be detected by cycle 40 were considered not to express the gene being assayed.
Statistical analysis
Data from experiment 1 was analysed by the Student's t-test. Data from experiments 2-4 were analysed by the Tukey-Kramer test. All statistics was performed using the commercial package StatViev (SAS Institute).
RESULTS
In experiment 1, the effect of fasting on ghrelin expression and concentration in oneweek-old chickens were examined. Twenty four h of fasting significantly increased ghrelin mRNA levels in proventriculus (from 0.0620±0.007 ghrelin/18sRNA to 0.110±0.012 ghrelin/18sRNA Mrna; P<0.01; Figure 1 ). Furthermore, ghrelin 
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Ghrelin/18sRNA mRNA peptide concentration in all experimental tissues (proventriculus; P<0.01; pituitary, adrenal glands; P<0.05) were increased significantly following 24 h of feed deprivation (Figures 2 a-d) . The date indicated that plasma ghrelin levels were also significantly (P<0.01) increased by fasting (Figure 2b ). In experiment 2, the results indicated that the ip-injected ghrelin strongly inhibited feed intake in dose-and time-dependent manner (P<0.05; Figure 3) .
Feed intake was already suppressed after 30 min and remained decreased until 2 h after injection of both ghrelin doses. In addition, peripheral ghrelin-elicited corticosterone release was observed during 2 h of the experiment in dose-and time-dependent manner (P<0.05; Figure 4 ). In experiment 3, the effect of ip-administrated chicken ghrelin and/or antagonists of CRF receptors (astressin) and glucocorticoids antagonists on feed intake and plasma corticosterone levels were investigated. Astressin in combination with ghrelin attenuated the inhibitory effect of ghrelin on feed intake 60 min after ip-injection (P<0.05; Figure 5 ). The results indicated that co-administration of CRF-receptor antagonist with chicken ghrelin partially reversed ghrelin-induced corticosterone release. Astressin alone decreased plasma corticosterone levels at 60 min from 10.903±0.500 ng/ml to 8.604±0.313 ng/ml (P<0.05; Figure 6 ). Furthermore, ip-injected astressin declined plasma ghrelin levels one hour after treatment (P<0.05; Figure 7) . The data indicated that the peripheral administration of glucocorticoids antagonist (RU486) significantly inhibited feed intake during one h after injection (P<0.05; Figure 8) . Additionally, the co-injection of RU486 with ghrelin strongly enhanced inhibitory effect of ghrelin on feed intake at least 60 min after treatment (P<0.05; Figure 8 ). RU486 alone declined plasma corticosterone levels during one hour of the experiment. The glucocorticoids antagonist in combination with ghrelin attenuated ghrelin-induced corticosterone 
DISCUSSION
Ghrelin expression and secretion are associated with feeding status. Toshinai et al. (2001) reported that plasma ghrelin levels increased during 12-h fasting and returned to the basal concentration after re-feeding. The current study demonstrated an increase in ghrelin mRNA expression and peptide concentration in proventriculus after 24 h fasting similar to the previous results reported by Geelissen et al. (2006) . Furthermore, we observed an increase in ghrelin concentration in homogenates from pituitary and adrenal glands. The obtained results support the idea that ghrelin acts either directly on adrenal glands or indirectly through CRF -expressing neurons.
It is known that ghrelin is an anorexigenic peptide in chicken when injected centrally (Kaiya et al., 2007) . However, controversial effects of peripheral ghrelin on appetite have been reported. Intravenous injection of chicken ghrelin (1 nmol/100 g BW) inhibited feed intake during the first h after administration in 7-day-old broiler chickens (Geelissen et al., 2006) , while ip injection of 0.6 nmol/100 g BW of ghrelin does not change feed intake in 8-day-old Leghorn chickens during 2 h of experiment (Kaiya et al., 2007) . Moreover, Shousha et al. (2005) reported that low doses of ghrelin injected ip (0.4 and 0.8 nmol/100 g BW) stimulated appetite in adult Japanese quail. Although, the present results show that ip injection of chicken ghrelin with both high and low doses (2 and 0.5 nmol/100 g BW) significantly suppressed feed intake throughout the experimental period (from 30 to 120 min after administration). This difference may be due to the dissimilar effect of ghrelin on appetite between egg-laying type and meat-type chickens (Nie et al., 2004; Richards, 2003) . Saito et al. (2005) were first to report that the activity of chicken ghrelin is not mediated by NPY/AgRP-producing neurons but through the CRH -expressing neurons in hypothalamus which cause the inhibition of the appetite and activate the HPA axis inducing an increase in plasma corticosterone levels. Similarly to the previous study, in which intravenous injected ghrelin stimulated corticosterone release (Kaiya et al., 2002) , we observed that ip ghrelin administration significantly increase plasma corticosterone concentration in 7-day-old chickens and the effect is distinctly time and dose dependent. Moreover, the ghrelin-elicited corticosterone release and ghrelin-induced anorexia were partially attenuated by the co-injection of astressin, CRH receptors antagonist, during at least one h after administration. CRH and receptors that were initially characterized in the brain (where they inhibit feed intake) have recently been shown to be widely expressed in peripheral tissues, including the gastrointestinal tract. In mammals, researchers recently reported that des-acyl ghrelin is also a biologically active peptide which inhibits feed intake by CRH type 2 receptors (Chen et al., 2005) . The effect was not altered by capsaicin treatment which indicate that peripheral des-acyl ghrelin may induce anorexigenic function by direct activation of brain receptor by crossing the blood-brain barrier but not by the activation of vagal afferent pathways (Chen et al., 2005) . Although little is known about des-ghrelin in birds, Saito et al. (2002) reported that icv injection of des-ghrelin did not change feed intake in neonatal chicks. However, in the present study, we reported that activity of ghrelin was restricted after peripheral blocking of CRH receptors in 7-day-old chickens.
In addition, we also investigated the influence of injection the glucocorticoids receptor antagonist (RU 486) on ghrelin activity. The administration of RU486 strongly inhibited feed intake throughout the experimental period. The glucocorticoids receptor antagonist in combination with chicken ghrelin strongly enhanced the inhibitory effect of ghrelin on appetite during at least 2 h after treatment. The result may suggest that the blocking corticosterone effect by RU 486 caused an increase CRH concentration which provided to improve ghrelin-induced anorexia. The HPA axis plays a critical role in the regulation of energy balance. An increase of feed intake is associated with glucocorticoid excess. Inversely, removal of glucocorticoid by adrenalectomy (ADX) reduces hyperphagia and body weight in rodents. In mammals it has been previously reported that administration of synthetic glucocorticoid (dexamethasone 200 µg/ day) increased GHS-R mRNA levels in adrenalectomized rats. Furthermore, an addition of dexamethasone to pituitary cell cultures increased GHS-R mRNA levels in a dose-and time-dependent manner while supplementation of the transcriptional inhibitor (actinomycin A) completely blocked the stimulatory effect of glucocorticoids in rat (Tamura et al., 2000) . These findings suggest that the suppression of corticosterone release may cause a decrease in expression of GHS-R and in consequence the limitation in ghrelin activity. Little is known about the influence of corticosterone on stimulating GHS-R gene transcription in chicken. The result of the present study indicate that the antagonist of glucocorticoid in combination with chicken ghrelin partially reversed stimulatory effect of ghrelin on corticosterone release at 60 min after injection. It is possible that similar to the mechanism in mammals, in which the lowered level of glucocorticoid is a restricted factor of growth hormone secretagagogue receptor (GHS-R) mRNA expression also in chickens. This hypothesis needs to be examined in future.
In conclusion, our data indicate that appetite -suppressive action of peripheral ghrelin is associated with activity of HPA axis in chickens.
